Florence Broussais is an expert in Hematology at Hospices Civils de Lyon (France). Florence Broussais has authored 109 publications, the most recent in 2023, and is an investigator in 2 clinical trials. SLR score: 299 (community average: 125). How the SLR is computed.

LeadR Profile

Florence Broussais Hospices Civils de Lyon France
299 ScienceLeadR Reputation 299
Network Map

Hematology

Subspecialties:

Full career – Last 3 years

Main Topics

Publications and Clinical Studies

Publications – Clinical Studies

Profile data updated on

Expert Rankings

Top experts on the MeSH terms this expert works on

Organizations

Career arc: 2010 - 2026

Source: PubMed

CALYM

Publications Synthesis

Sources: PubMed, OpenAlex

Number : 109

Citations

Citations: 3 099 1st author: 13 Last author: 3 Unique author: 0


Breakdown by type

Click a legend label to hide or show it in the chart.

Latest Publications

5 most recent indexed articles

Source: Pubmed

Title Journal Year Citations
1281 Prediction of response to immunotherapy using machine learning and tumor kinetic modeling incorporating CD8 PET imaging analysis
OpenAlex W4388048333 — positron-emission tomography, neoplasms, immunotherapy, machine learning, learning
Regular and Young Investigator Award Abstracts20230
Women in Lymphoma: A 4-year journey in promoting gender equity.
PMID 37231947 — hematology, lymphoma, gender equity, medical oncology
Hematol Oncol20232
Application of the Lugano Classification for Initial Evaluation, Staging, and Response Assessment of Hodgkin and Non-Hodgkin Lymphoma: The PRoLoG Consensus Initiative (Part 2-Technical).
PMID 35835581 — nuclear medicine, hodgkin disease, classification, lymphoma, non-hodgkin
J Nucl Med20229
Application of the Lugano Classification for Initial Evaluation, Staging, and Response Assessment of Hodgkin and Non-Hodgkin Lymphoma: The PRoLoG Consensus Initiative (Part 1-Clinical).
PMID 35835580 — nuclear medicine, hodgkin disease, classification, lymphoma, non-hodgkin
J Nucl Med202234
Outcomes of patients with aggressive B-cell lymphoma after failure of anti-CD19 CAR T-cell therapy: a DESCAR-T analysis.
PMID 36122385 — hematology, lymphoma, b-cell, cells, therapeutics, t-lymphocytes, c-reactive protein, disease-free survival, b-lymphocytes, progression-free survival, car-t cell
Blood202290

Clinical Studies 2

Sources: ClinicalTrials, EU CTIS

Synthesis

By phase:

N/A 1
Phase 1 1

By status:

Completed 1
Recruiting 1

By type:

Interventional 1
Observational 1

By Monocentric/Multicentric:

monocentric 1
multicentric2to4 0
multicentric5to9 0
multicentricup10 1

Main Topics

LeadR Networks

Main global connection map